# Shanghai Kechow Pharma

Source: https://onco.cc/companies/shanghai-kechow-pharma/  
OnCo record `shanghai-kechow-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Shanghai Kechow Pharma is a China-based pharmaceutical company running 3 late-stage cancer trials of tunlametinib, Tunlametinib and HL-085 in melanoma, colorectal cancer and rare cancers of childhood.

## Summary

Shanghai Kechow Pharma, based in Shanghai, China, is a pharmaceutical company. Kechow Pharma is a Shanghai-based pharmaceutical company engaged in independent, intellectual-property-driven innovative drug research and development, focused on oncology and free-radical-related diseases. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing tunlametinib, Tunlametinib and HL-085 in melanoma, colorectal cancer and rare cancers of childhood. The largest, NCT06008106 (Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma), plans to enrol 165 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Shanghai Kechow Pharma, Inc.
- Tags: ctgov-sponsor
- HQ: Shanghai
- Type: pharma
- Website: https://kechowpharma.com

## Sources

- Official website: https://kechowpharma.com
- ClinicalTrials.gov: trials led by Shanghai Kechow Pharma: https://clinicaltrials.gov/search?lead=Shanghai%20Kechow%20Pharma%2C%20Inc.

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Rare cancers of childhood (NCI PDQ umbrella)](https://onco.cc/cancers/rare-childhood-cancers/)
- drugs: [KC1036](https://onco.cc/drugs/kc1036/), [Tunlametinib](https://onco.cc/drugs/tunlametinib/)
- trials: [Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma](https://onco.cc/trials/nct06008106/), [Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer](https://onco.cc/trials/nct06008119/)

---
JSON: https://onco.cc/api/v1/entities/shanghai-kechow-pharma.json